Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy
April 9, Hebe Biotechnology Pte Ltd ("Hebe Bio"), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD, MBA as Chief Development Officer (CDO), effective April 1, 2025. Dr. Hentze will lead the global development strategy for the company's next-generation GLP-1 receptor agonist (GLP-1 RA), a cutting-edge weight loss therapy […]